334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
| Autor: | Bulat, I., Maglakelidze, M., Krastev, B., Arkenau, H-T., Murias, C., Baird, R.D., Roylance, R., Wardley, A.M., Crijanovschi, A., Gogiladze, M., Lu, Y., McCullough, A., Jain, S., Wolfgang, C.D., Malik, R., Beelen, A.P. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S380-S380 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|